Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.

Thrombosis research - 1 Aug 2012

Kreutz Rolf P, Breall Jeffrey A, Kreutz Yvonne, Owens Janelle, Lu Deshun, Bolad Islam, von der Lohe Elisabeth, Sinha Anjan, Flockhart David A

Abstract excerpt

INTRODUCTION: Clopidogrel inhibits ADP mediated platelet aggregation through inhibition of the P2Y12 receptor by its active metabolite. Thrombin induces platelet aggregation by binding to protease activated receptor-1 (PAR-1), and inhibition of PAR-1 has been evaluated in patients treated with cl...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clopidogrel
Share to Percutaneous Coronary Intervention
Share to Platelet Aggregation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Platelet Aggregation Inhibitors

Share to Receptor, PAR-1

Share to Receptors, Thrombin

Share to Thrombosis

Share to Ticlopidine

Source

Open in PubMed Open full text

Identifiers

PMID: 22459907
DOI: 10.1016/j.thromres.2012.02.049
PMCID: PMC3965578

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22459907-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.PMID 22459907Read ↗

Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.Semantic proximity Read ↗

Identification of a Distinct Platelet Phenotype in the Elderly: ADP Hypersensitivity Coexists With Platelet PAR (Protease-Activated Receptor)-1 and PAR-4-Mediated Thrombin Resistance.Semantic proximity Read ↗

P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease.Semantic proximity Read ↗

PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.Semantic proximity Read ↗

Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey.Semantic proximity Read ↗

Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet functionSemantic proximity Read ↗

Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.Semantic proximity Read ↗

Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?Semantic proximity Read ↗

Biology and Pharmacology of the Platelet P2Y12 ReceptorSemantic proximity Read ↗

Ex-vivo antiplatelet effects of oral anticoagulantsSemantic proximity Read ↗

Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics.Semantic proximity Read ↗

The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.